Imagion Biosystems today announced “Notice of change of interests of substantial holder — IBX.”
View Form 604 Notice of change of interests of substantial holder — IBX.
Positive independent review sets priority path to market for MagSense® Technology
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance